General Category > Health/Education

Paxlovid Doesn’t Work in Many Vaccinated People: Pfizer Study

(1/1)

Hoodat:
Paxlovid Doesn’t Work in Many Vaccinated People: Pfizer Study

Zachary Stieber  |  4/4/2024

Pfizer’s COVID-19 drug did not work for many vaccinated people, according to a new paper from the company’s scientists.

There was not a statistically significant difference between Paxlovid and placebo recipients in terms of time to alleviation of symptoms, the scientists reported in the new paper.

The paper, published by the New England Journal of Medicine, describes the results of a company-funded phase 2-3 trial of the drug, which is also known as nirmatrelvir.  .  .

.  .  .  Dr. Vinay Prasad, an epidemiology professor at the University of California, San Francisco, who was not involved with the research, said on social media platform X that the trial showed Paxlovid “doesn’t work in vaccinated people.”

“It was embarrassing to watch the administration and many ID doctors recommend this without any credible data,” he wrote, criticizing the government for spending north of $12 billion for courses of the treatment without much trial data.”

Pfizer and the White House did not respond to requests for comment.

https://www.theepochtimes.com/health/paxlovid-doesnt-work-in-many-vaccinated-people-pfizer-study-5621617

mountaineer:
 I'm shocked, I tell you.

mountaineer:
Is Paxlovid a Dud?
By Maryanne Demasi
April 13, 2024 
--- Quote ---Of all the antiviral drugs for Covid-19, Pfizer’s Paxlovid has been the most successful. Not for its safety and efficacy, but for its ability to earn the company billions in profits despite being largely ineffective for most people.

In November 2021, before any data had emerged, the Biden Administration committed to purchasing 10 million treatment courses of Paxlovid worth $5.3 billion, pending authorisation by the US drug regulator.

One month later, Paxlovid was granted emergency use authorisation (EUA) by the FDA for use in adult and paediatric populations, 12 years or older.

The authorisation was based on early trial data showing the drug could reduce hospitalisations or death (89% relative risk reduction, 6% absolute risk reduction) in high-risk patients who were unvaccinated and had no prior exposure to Covid-19.  ...

By July 2022, however, Pfizer stopped enrolling participants “due to a very low rate of hospitalization or death observed in the standard-risk patient population.”

In a press release, the company announced that Paxlovid failed to impact its “novel primary endpoint of self-reported, sustained alleviation of all symptoms for four consecutive days.” 

In other words, Paxlovid – a combination of nirmatrelvir and ritonavir – made no significant difference in alleviating symptoms of Covid-19 compared to placebo among non-hospitalised patients. ...
--- End quote ---
Read entire article at Brownstone Institute

Hoodat:
Can US Taxpayers get their $12 billion back?  If this was any other company, some federal jury would be handing out civil judgments in the billions.  And federal prosecutors would be seeking fraud convictions against high level executives.  But in this case, Pfizer and the government were in on it together.

The only question that remains:  How much of that $12 billion ended up in Democrats campaign coffers for 2022 and 2024?

libertybele:

--- Quote from: mountaineer on April 13, 2024, 03:37:02 pm ---Is Paxlovid a Dud?
By Maryanne Demasi
April 13, 2024  Read entire article at Brownstone Institute

--- End quote ---

I question what side effects have been experienced from this drug that didn't work?? Or was this a drug that was some sort of saline solution that cost taxpayers a small fortune?

Navigation

[0] Message Index